Neurocognition After Radiotherapy in CNS- and Skull-base Tumors
Trial Parameters
Brief Summary
The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning. All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation) Exclusion Criteria: * Patients with tumours with poor prognostic characteristics: * Incompletely resected IDH-wild-type glioma * Completely resected IDH-wild-type and MGMT-promotor unmethylated glioma * grade III meningioma * H3K27M+ midline glioma * Patients with tumours requiring craniospinal irradiation (CSI)/whole ventricular irradiation (WVI) * Hypofractionated/stereotactic radiation (fraction sizes \> 2 Gy per fraction) * Inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient Dutch language proficiency * Mental retardation documented before diagnosis * Pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders) * Re